Ian Chau, MD, of the Royal Marsden Hospital, discusses the continuum of care in esophageal and gastric cancers and the multiple active lines of treatment. Routine adoption of genomic testing may lead to further refinement of current treatment and more options in the future.
Julien Edeline, MD, of the Centre Eugène Marquis, discusses study findings on gemcitabine and oxaliplatin vs surveillance following surgery for localized biliary tract cancer (Abstract 225).
Cynthia L. Sears, MD, of Johns Hopkins University School of Medicine, summarizes her keynote talk on microbes, microbiota, and colon cancer. Next-generation sequencing combined with biologic studies suggests that most colorectal cancer cases have specific microbiome associations.
Sarah E. Hoffe, MD, of the Moffitt Cancer Center, discusses the controversial role of radiation in the treatment of pancreatic cancer, recent advances in delivering short courses of high-dose stereotactic body radiation therapy, and how best to integrate this new modality in borderline and locally advanced disease.
Cornelis van de Velde, MD, PhD, of Leiden University Medical Center, discusses the International Watch & Wait database, established to track evidence on organ-preserving strategies in patients with rectal cancer (Abstract 521).
Karyn A. Goodman, MD, of the University of Colorado School of Medicine, discusses initial study findings on PET scan–directed combined-modality therapy for esophageal cancer (Abstract 1).
